REGULATORY

• LDP Pharma Study Group Proposes Removing Cap for Social Security Costs
  May 23, 2023

• Ophthalmic Mitomycin, OD Tablets for Takecab and Tarlige to Get Listing on May 24
  May 23, 2023

• MHLW Cancels Expert Panel Meeting on May 23, Report Delayed
  May 23, 2023

• Ferring’s Oral Budesonide for UC Treatment Up for Advisor Review on June 2
  May 22, 2023

• PMDA Reviewing Safety Risks for Opdivo, Yervoy
  May 22, 2023

• Novo Mum over Pass on Wegovy Listing in May
  May 19, 2023

• Japan Eyes Pilot Program for OTC-Switching of Emergency Contraceptives, Public Commenters Overwhelmingly Positive
  May 18, 2023

• LDP Committee Calls for Setting Up Asian Hub of PMDA
  May 18, 2023

• Industry Associations Stress Special Cost Structure of SaMD in Chuikyo Hearing
  May 18, 2023

• Market Expansion Re-Pricing to Hit Tarlige, Entresto, Verzenio; Spillover to 2 Other Meds
  May 18, 2023

• Deregulation Panel Eyes Use of Medical Data “Without Patient Consent”
  May 17, 2023

• LDP Project Team to Finalize Pharma Policy Proposal for Honebuto by May-End, Submit It to Prime Minister
  May 17, 2023

• Create Command Tower to Integrate Innovation Support and Drug Pricing Policy: LDP Project Chief
  May 17, 2023

• Chuikyo OKs Listing of Omvoh, Entyvio SC, Besremi, and More; Biggest Sales Outlook for Lilly Drug
  May 17, 2023

• Novo’s Obesity Drug Wegovy Skips May Listing, Sobi’s Empaveli Too
  May 17, 2023

• Cancer Meds from Servier, Taiho, Pfizer’s AA Drug Up for Panel Review on May 29
  May 16, 2023

• MHLW Issues ICH E19-Based Guideline on Selective Approach to Safety Data Collection in Clinical Trials
  May 16, 2023

• 68.3% of Public Comments Supported Mefeego Approval: MHLW
  May 16, 2023

• G7 Health Chiefs Vow to Spur Antibiotic and Dementia Drug Development, Access to Vaccines
  May 15, 2023

• Gene Therapy Luxturna Up for MHLW Panel Review on May 26
  May 15, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 82
• 83
• 84
• 85
• 86
• 87
• 88
• 89
• 90
• …
• Next ›
• 最終 »